In the published article, there was an error in the Funding statement. The section originally stated that “COST is supported by the EU Framework Program Horizon 2020”, while it should refer to “Horizon Europe”. The correct Funding statement appears below.
“The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was developed within the scope of projects with references UIDB/04501/2020 and https://doi.org/10.54499/UIDB/04501/2020, UIDP/04501/2020 and https://doi.org/10.54499/UIDP/04501/2020, 2022.03217.PTDC and DOI 10.54499/2022.03217.PTDC, financially supported by national funds (OE), through FCT - Fundação para a Ciência e Tecnologia, I.P./MCTES. This work was also supported by the World Scleroderma Foundation and Edit Busch Stiftung (MAPFib). This work has been supported by Ministry of Science, Technological Development and Innovation, Republic of Serbia through Grant Agreement with University of Belgrade, Faculty of Medicine No: 451-03-66/2024-03/200110. This work was funded by the Ministry of Science, Technological Development and Innovation, Republic of Serbia through Grant Agreement with University of Belgrade-Faculty of Pharmacy No: 451-03-47/2023-01/200161. This work was supported by the Wellcome Trust (225021/Z/22/Z). This work was supported by the Swedish Cancer Society (22 2221.Pj.01.H) and Mrs. Berta Kamprad’s Cancer Foundation (FBKS-2022-8-368). This work was supported by the Scientific and Technological Research Council of Turkey- TUBITAK (119S447 and 22AG077). This work was also supported by European Cooperation in Science and Technology (COST) Action CA20117 Mye-InfoBank (www.mye-infobank.eu); COST is supported by the EU Framework Program Horizon Europe.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
tertiary lymphoid structures (TLS), tertiary lymphoid organs (TLO), dendritic cells (DC), anti-tumor immunity, autoimmunity
Citation
Reste M, Ajazi K, Sayi-Yazgan A, Jankovic R, Bufan B, Brandau S, Bækkevold ES, Petitprez F, Lindstedt M, Adema GJ and Almeida CR (2025) Corrigendum: The role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseases. Front. Immunol. 16:1538818. doi: 10.3389/fimmu.2025.1538818
Received
03 December 2024
Accepted
28 January 2025
Published
07 February 2025
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
16 - 2025
Updates
Copyright
© 2025 Reste, Ajazi, Sayi-Yazgan, Jankovic, Bufan, Brandau, Bækkevold, Petitprez, Lindstedt, Adema and Almeida.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Malin Lindstedt, malin.lindstedt@immun.lth.se; Gosse J. Adema, Gosse.Adema@radboudumc.nl; Catarina R. Almeida, cra@ua.pt
†These authors have contributed equally to this work and share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.